Coagulation disorders in adults with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a scoping review
DOI:
https://doi.org/10.32385/rpmgf.v37i5.13086Palabras clave:
SARS virus, Blood coagulation disorders, Anticoagulants, Platelet aggregation inhibitors, ReviewResumen
Objectives: To summarize published information on coagulation disorders in patients with SARS-CoV-2 infection, namely its characteristics, pathophysiology, diagnosis, and response to anticoagulant or antiplatelet therapy, either prophylactic or therapeutic.
Methods: A scoping review was conducted according to both Joanna Briggs Institute Guidelines on Scoping Reviews and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Scoping Review guidelines (PRISMA-ScR). A search on the MEDLINE®, SciELO®, and Web of Science® databases was performed between the 1st and 2nd May 2020. The articles selection was divided into three sequential stages: based on title, on abstract, and full article reading. At each stage, articles were assessed against the inclusion and exclusion criteria and accepted or rejected accordingly. The data were then charted, and the relevant evidence was summarized.
Results: After selection, 106 records were obtained. Of those, 36 corresponded to letters, 28 to original studies, 25 to reviews, and 14 to case reports; one metanalysis, one commentary, and one consensus paper were also included. Results have shown an association between COVID-19 and thrombotic complications, although different kinds of events and frequency rates were found. The triad inflammation, endothelial dysfunction, and coagulopathy seem to underly pathophysiological changes. Laboratory and imaging techniques may be useful for an adequate intervention. Prophylaxis with parenteral anticoagulants, preferably Low Molecular Weight Heparin (LMWH), in an intermediate dose between the commonly used ones for prophylaxis or treatment is indicated to hospitalized patients, especially those having a severe illness. It should be kept during a variable period after discharge, in an individualized patient-based approach. Therapeutical anticoagulation seems not to differ significantly from other disease settings.
Conclusions: Various uncertainties persist at coagulation disorders’ approach in patients with SARS-CoV-2 infection. The existing information has its origin mainly in the hospital setting and less robust sources. Thus, well-designed, randomized controlled clinical trials are needed to sustain clinical decisions at all stages.
Descargas
Referencias
European Centre for Disease Prevention and Control. Latest evidence on COVID-19 [homepage]. ECDC; 2019 [updated 2021 May 21; cited 2020 Jun 17]. Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence
World Health Organization. Rolling updates on coronavirus disease (COVID-19) [homepage]. WHO; 2019 [updated 2020 Jul 31; cited 2020 Jun 17]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen
Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [homepage]. CDC; 2019 [updated 2021 Seb 16; cited 2020 Jun 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
McIntosh K. COVID-19: clinical features. UpToDate [Internet]; 2020 [updated 2021 Jun 10; cited 2020 Jun 17]. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-clinical-features?topicRef=126981&source=see_link#H4079606749
Peters MD, Godfrey CM, McInerney P, Munn Z, Tricco AC, Khalil H. Scoping reviews [homepage]. In: Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. The Joanna Briggs Institute; 2020. chapter 11. Available from: https://wiki.jbi.global/display/MANUAL/Chapter+11%3A+Scoping+reviews
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73.
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in medical literature. Am Fam Physician. 2004;69(3):548-56.
Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123(17):2605-13.
Van Gorp EC, Suharti C, ten Cate H, Dolmans WM, van der Meer JW, ten Cate JW, et al. Review: Infectious diseases and coagulation disorders. J Infect Dis. 1999;180(1):176-86.
Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VE, Meijers JC, et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012;84(10):1680-96.
Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326(7403):1358-62.
Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-61.
Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis. 2011;52(2):e14-7.
Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015;19(1):287.
Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection: a scoping review. Thromb Res. 2020;192:152-60.
Song JC, Wang G, Zhang W, Zhang Y, Li WQ, Zhou Z. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020;7(1):19.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1-13.
Safari S, Mehrani M, Yousefifard M. Pulmonary thromboembolism as a potential cause of clinical deterioration in COVID-19 patients: a commentary. Arch Acad Emerg Med. 2020;8(1):e52.
Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26(9):1259.e5-e7.
de Girolamo L, Peretti GM, Maffulli N, Brini AT. Covid-19: the real role of NSAIDs in Italy. J Orthop Surg Res. 2020;15(1):165.
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-7.
Scialpi M, Scialpi S, Piscioli I, Scalera GB, Longo F. Pulmonary thromboembolism in critical ill COVID-19 patients. Int J Infect Dis. 2020;95:361-2.
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40.
Akima S, McLintock C, Hunt BJ. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(8):2057-8.
Casey K, Iteen A, Nicolini R, Auten J. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020;38(7):1544.e1-e3.
Li XY, Du B, Wang YS, Kang HY, Wang F, Sun B, et al. [The keypoints in treatment of the critical coronavirus disease 2019 patient]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(4):277-81. Chinese
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319.
Mei H, Hu Y. [Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19]. Chin J Hematol. 2020;41(3):185-91. Chinese
Zhou B, She J, Wang Y, Ma X. Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. J Thromb Thrombolysis. 2020;50(1):229-32.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9.
Zou Y, Guo H, Zhang Y, Zhang Z, Liu Y, Wang J, et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends. 2020;14(4):285-9.
Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358-64.
Khalili N, Haseli S, Iranpour P. Lung ultrasound in COVID-19 pneumonia: prospects and limitations. Acad Radiol. 2020;27(7):1044-5.
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.
Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud T, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. 2020;297(1):E216-22.
Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020;55(5):2001028.
Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167-9.
Spyropoulos AC, Ageno W, Barnathan ES. Hospital-based use of thromboprophylaxis in patients with COVID-19. Lancet. 2020;395(10234):e75.
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023-6.
Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, Gerber B, Graf L, et al. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19: a Swiss consensus statement by the Working Party Hemostasis. Swiss Med Wkly. 2020;150:w20247.
Tang N. Response to 'Pulmonary thrombosis in 2019-nCoV pneumonia?' J Thromb Haemost. 2020;18(6):1513-4.
Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18(7):1548-55.
Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19: posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología [Recommendations on antithrombotic treatment during the COVID-19 pandemic: position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]. Rev Esp Cardiol. 2020;73(9):749-57. Spanish
Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-7.
Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Rep. 2020;2(9):1379-82.
Henry BM, de Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8.
Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-73.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47.
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6.
Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-6.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up (JACC state-of-the-art review). J Am Coll Cardiol. 2020;75(23):2950-73.
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID‐19. J Thromb Haemost. 2020;18(7):1559-61.
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002.
Bozzani A, Arici V, Franciscone MM, Danesino V, Cascina A, Ticozzelli G, et al. Severe acute respiratory syndrome coronavirus 2 infection and the upper limb deep vein thrombosis risk. Ann Vasc Surg. 2020;66:11-3.
Griffin DO, Jensen A, Khan M, Chin J, Chin K, Saad J, et al. Pulmonary embolism and increased levels of d-dimer in patients with coronavirus disease. Emerg Infect Dis. 2020;26(8):1941-3.
Obi AT, Tignanelli CJ, Jacobs BN, Arya S, Park PK, Wakefield TW, et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019;7(3):317-24.
MacDougall K, Spyropoulos AC. New paradigms of extended thromboprophylaxis in medically ill patients. J Clin Med. 2020;9(4):1002.
Foch E, Allou N, Vitry T, Masse L, Allyn J, Andre M, et al. Pulmonary embolism in returning traveler with COVID-19 pneumonia. J Travel Med. 2020;27(5):taaa063.
Li HC, Ma J, Zhang H, Cheng Y, Wang X, Hu ZW, et al. [Thoughts and practice on the treatment of severe and critical new coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(5):396-400. Chinese
Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-51.
Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, et al. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost. 2020;18(8):2058-60.
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504-7.
Lee SG, Fralick M, Sholzberg M. Coagulopathy associated with COVID-19. CMAJ. 2020;192(21):E583.
Libby P. The heart in COVID19: primary target or secondary bystander? JACC Basic Transl Sci. 2020;5(5):537-42.
Xing C, Li Q, Du H, Kang W, Lian J, Yuan L. Lung ultrasound findings in patients with COVID-19 pneumonia. Crit Care. 2020;24(1):174.
Tavazzi G, Civardi L, Caneva L, Mongodi S, Mojoli F. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive Care Med. 2020;46(6):1121-3.
Marone EM, Rinaldi LF. Upsurge of deep venous thrombosis in patients affected by COVID-19: preliminary data and possible explanations. J Vasc Surg Venous Lymphat Disord. 2020;8(4):694-5.
Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology. 2020;296(3):E186-8.
Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging. 2020;101(5):321-2.
Sławiński G, Lewicka E. What should a cardiologist know about coronavirus disease 2019? Kardiol Pol. 2020;78(4):278-83.
Fabre O, Rebet O, Carjaliu I, Radutoiu M, Gautier L, Hysi I. Severe acute proximal pulmonary embolism and COVID-19: a word of caution. Ann Thorac Surg. 2020;110(5):e409-11.
Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998-1000.
Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC Basic Transl Sci. 2020;5(5):518-36.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352-71.
Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(0):E006. Chinese
Marongiu F, Grandone E, Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost. 2020;18(6):1511-3.
Lushina N, Kuo JS, Shaikh HA. Pulmonary, cerebral, and renal thromboembolic disease in a patient with COVID-19. Radiology. 2020;296(3):E181-3.
Fogarty H, Townsend L, Cheallaigh CN, Bergin C, Martin-Loeches I, Browne P, et al. COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1044-9.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142(1):68-78.
Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels. Radiology. 2020;296(3):E189-91.
Dolhnikoff M, Duarte-Neto AN, Monteiro RA, Silva LF, Oliveira EP, Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517-9.
Bouaziz JD, Duong TA, Jachiet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID‐19: a French observational study. J Eur Acad Dermatol Venereol. 2020;34(9):e451-2.
Zangrillo A, Beretta L, Scandroglio AM, Monti G, Fominskiy E, Colombo S, et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc. 2020;22(3):200-11.
Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-90.
Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020;100(6):794-800.
Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92(9):1533-41.
Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-8.
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.
Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost. 2020;46(3):379-82.
Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost. 2020;18(8):2071-2.
Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-8.
Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116-20.
Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62.
Xiong M, Liang X, Wei YD. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Br J Haematol. 2020;189(6):1050-2.
Saba L, Sverzellati N. Is COVID evolution due to occurrence of pulmonary vascular thrombosis? J Thorac Imaging. 2020;35(6):344-5.
Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752-5.
Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID‐19. J Thromb Haemost. 2020;18(6):1469-72.
Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;31(4):490-6.
Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2021;51(4):1107-10.
Tan CW, Low JG, Wong WH, Chua YY, Goh SL, Ng HJ. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. Am J Hematol. 2020;95(7):E156-8.
Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020;42(Suppl 1):19-20.
Zotzmann V, Lang CN, Bamberg F, Bode C, Staudacher DL. Are subpleural consolidations indicators for segmental pulmonary embolism in COVID-19? Intensive Care Med. 2020;46(6):1109-10.
Yao N, Wang SN, Lian JQ, Sun YT, Zhang GF, Kang WZ, et al. [Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region]. Zhonghua Gan Zang Bing Za Zhi. 2020;28(3):234-9. Chinese
Harsch IA, Skiba M, Konturek PC. Severe acute respiratory syndrome coronavirus 2 pneumonia and pulmonary embolism in a 66-year-old female. Pol Arch Intern Med. 2020;130(5):438-9.
Cellina M, Oliva G. Acute pulmonary embolism in a patient with COVID-19 pneumonia. Diagn Interv Imaging. 2020;101(5):325-6.
Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362-3.
Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment. J Thromb Haemost. 2020;18(8):2060-3.
Lacour T, Semaan C, Genet T, Ivanes F. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients. Catheter Cardiovasc Interv. 2021;97(2):E241-3.
Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020;18(6):1521-2.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2021 Portuguese Journal of Family Medicine and General Practice
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores otorgan a RPMGF el derecho exclusivo de publicar y distribuir en medios físicos, electrónicos, de radiodifusión u otros medios que pueda existir el contenido del manuscrito identificado en esta declaración. También otorgan a RPMGF el derecho de usar y explorar el presente manuscrito, es decir, de ceder, vender o licenciar su contenido. Esta autorización es permanente y entra en vigor desde el momento en que se envía el manuscrito, tiene la duración máxima permitida por la legislación portuguesa o internacional aplicable y tiene un alcance mundial. Los autores declaran además que esta transferencia se realiza de forma gratuita. Si la RPMGF informa a los autores que ha decidido no publicar su manuscrito, la cesión exclusiva de derechos cesa inmediatamente.
Los autores autorizan a RPMGF (oa una entidad que éste designe) a actuar en su nombre cuando considere que existe una infracción a los derechos de autor.
